482 related articles for article (PubMed ID: 16130441)
1. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
Miheller P; Muzes G; Zágoni T; Tóth M; Rácz K; Tulassay Z
Orv Hetil; 2005 Jul; 146(28):1477-80. PubMed ID: 16130441
[TBL] [Abstract][Full Text] [Related]
2. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease.
Franchimont N; Putzeys V; Collette J; Vermeire S; Rutgeerts P; De Vos M; Van Gossum A; Franchimont D; Fiasse R; Pelckmans P; Malaise M; Belaiche J; Louis E
Aliment Pharmacol Ther; 2004 Sep; 20(6):607-14. PubMed ID: 15352908
[TBL] [Abstract][Full Text] [Related]
3. Infliximab therapy improves the bone metabolism in fistulizing Crohn's disease.
Miheller P; Muzes G; Zagoni T; Toth M; Racz K; Tulassay Z
Dig Dis; 2006; 24(1-2):201-6. PubMed ID: 16699279
[TBL] [Abstract][Full Text] [Related]
4. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study.
Ryan BM; Russel MG; Schurgers L; Wichers M; Sijbrandij J; Stockbrugger RW; Schoon E
Aliment Pharmacol Ther; 2004 Oct; 20(8):851-7. PubMed ID: 15479356
[TBL] [Abstract][Full Text] [Related]
5. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
Gao Q; Hogezand RA; Lamers CB; Verspaget HW
Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
[TBL] [Abstract][Full Text] [Related]
6. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
7. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.
Lange U; Teichmann J; Müller-Ladner U; Strunk J
Rheumatology (Oxford); 2005 Dec; 44(12):1546-8. PubMed ID: 16263785
[TBL] [Abstract][Full Text] [Related]
8. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
[TBL] [Abstract][Full Text] [Related]
9. Use of infliximab in the treatment of Crohn's disease in children and adolescents.
Hyams JS; Markowitz J; Wyllie R
J Pediatr; 2000 Aug; 137(2):192-6. PubMed ID: 10931411
[TBL] [Abstract][Full Text] [Related]
10. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
[TBL] [Abstract][Full Text] [Related]
11. [Serum bone marker measurements in bone metabolism disorders associated with inflammatory bowel diseases].
Miheller P; Tóth M; Molnár E; Zágoni T; Rácz K; Tulassay Z
Orv Hetil; 2001 Jul; 142(29):1557-60. PubMed ID: 11494747
[TBL] [Abstract][Full Text] [Related]
12. Infliximab (Remicade), a new biological treatment for Crohn's disease.
D'Haens GR
Ital J Gastroenterol Hepatol; 1999; 31(6):519-20. PubMed ID: 10575573
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
[TBL] [Abstract][Full Text] [Related]
14. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
Hyder SA; Travis SP; Jewell DP; McC Mortensen NJ; George BD
Dis Colon Rectum; 2006 Dec; 49(12):1837-41. PubMed ID: 17041753
[TBL] [Abstract][Full Text] [Related]
15. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
Maser EA; Villela R; Silverberg MS; Greenberg GR
Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
[TBL] [Abstract][Full Text] [Related]
16. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study.
Thayu M; Leonard MB; Hyams JS; Crandall WV; Kugathasan S; Otley AR; Olson A; Johanns J; Marano CW; Heuschkel RB; Veereman-Wauters G; Griffiths AM; Baldassano RN;
Clin Gastroenterol Hepatol; 2008 Dec; 6(12):1378-84. PubMed ID: 19081527
[TBL] [Abstract][Full Text] [Related]
17. The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease.
Eivindson M; Grønbaek H; Skogstrand K; Thorsen P; Frystyk J; Flyvbjerg A; Dahlerup JF
Scand J Gastroenterol; 2007 Apr; 42(4):464-70. PubMed ID: 17454856
[TBL] [Abstract][Full Text] [Related]
18. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
[TBL] [Abstract][Full Text] [Related]
19. Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn's disease patients.
Di Sabatino A; Ciccocioppo R; Benazzato L; Sturniolo GC; Corazza GR
Aliment Pharmacol Ther; 2004 May; 19(9):1019-24. PubMed ID: 15113369
[TBL] [Abstract][Full Text] [Related]
20. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
